📊 SMNRW Key Takeaways
Is Semnur Pharmaceuticals, Inc. (SMNRW) a Good Investment?
Semnur Pharmaceuticals is in critical financial distress with negative stockholders' equity of -$20.8M, indicating technical insolvency. The company is burning $5.9M annually in operating cash while holding only $20K cash, creating immediate solvency risk. Operating margins of -320.8% and a liquidity ratio of 0.06x reflect a fundamental business model failure with high bankruptcy risk.
Why Buy Semnur Pharmaceuticals, Inc. Stock? SMNRW Key Strengths
- Maintains $50M revenue base despite operational crisis
- Operating in pharmaceutical sector with structural market demand
- Still has debt capacity theoretically if capital restructuring possible
SMNRW Stock Risks: Semnur Pharmaceuticals, Inc. Investment Risks
- Negative stockholders' equity of -$20.8M indicates balance sheet insolvency
- Cash position of $20K cannot sustain $5.9M annual burn rate
- Current ratio of 0.06x reflects critical liquidity crisis and inability to meet obligations
- Operating margins of -320.8% indicate severe operational dysfunction or catastrophic loss event
- Negative interest coverage ratio means zero debt servicing capability from operations
- 3320% YoY deterioration suggests major impairment, restructuring charge, or operational collapse
Key Metrics to Watch
- Remaining cash runway and monthly burn rate trajectory
- Emergency capital raise or debt restructuring announcements
- Path to positive operating income and cash flow generation
- Total liabilities reduction or debt forgiveness negotiations
- Stockholders' equity recovery to positive territory
Semnur Pharmaceuticals, Inc. (SMNRW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
SMNRW Profit Margin, ROE & Profitability Analysis
SMNRW vs Healthcare Sector: How Semnur Pharmaceuticals, Inc. Compares
How Semnur Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Semnur Pharmaceuticals, Inc. Stock Overvalued? SMNRW Valuation Analysis 2026
Based on fundamental analysis, Semnur Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Semnur Pharmaceuticals, Inc. Balance Sheet: SMNRW Debt, Cash & Liquidity
SMNRW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Semnur Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.02 indicates the company is currently unprofitable.
SMNRW Revenue Growth, EPS Growth & YoY Performance
SMNRW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $50.0M | -$194.6K | N/A |
| Q1 2025 | $50.0M | -$194.6K | N/A |
| Q3 2024 | $50.0M | -$40.9K | N/A |
| Q2 2024 | $50.0M | $264.3K | N/A |
| Q1 2024 | $50.0M | $264.3K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Semnur Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
SMNRW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Semnur Pharmaceuticals, Inc. (CIK: 0001913577)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SMNRW
What is the AI rating for SMNRW?
Semnur Pharmaceuticals, Inc. (SMNRW) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SMNRW's key strengths?
Claude: Maintains $50M revenue base despite operational crisis. Operating in pharmaceutical sector with structural market demand.
What are the risks of investing in SMNRW?
Claude: Negative stockholders' equity of -$20.8M indicates balance sheet insolvency. Cash position of $20K cannot sustain $5.9M annual burn rate.
What is SMNRW's revenue and growth?
Semnur Pharmaceuticals, Inc. reported revenue of $50.0M.
Does SMNRW pay dividends?
Semnur Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find SMNRW SEC filings?
Official SEC filings for Semnur Pharmaceuticals, Inc. (CIK: 0001913577) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SMNRW's EPS?
Semnur Pharmaceuticals, Inc. has a diluted EPS of $-0.78.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SMNRW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Semnur Pharmaceuticals, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SMNRW stock overvalued or undervalued?
Valuation metrics for SMNRW: ROE of N/A (sector avg: 15%), net margin of -320.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SMNRW stock in 2026?
Our dual AI analysis gives Semnur Pharmaceuticals, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SMNRW's free cash flow?
Semnur Pharmaceuticals, Inc.'s operating cash flow is $-5.9M, with capital expenditures of N/A. FCF margin is -11.7%.
How does SMNRW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -320.8% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.06 (avg: 2).